C92.6

Clinical Causes: Genetic mutations affecting the MLL gene located at chromosome 11q23. Previous exposure to chemotherapy or radiation therapy, which may increase risk. Certain occupational exposures to chemicals or toxins. Family history of leukemia or other hematologic malignancies. Age-related genetic changes, particularly in older adults.

Key Symptoms: Fatigue and weakness due to anemia. Unexplained fever or infections resulting from a weakened immune system. Easy bruising or bleeding, including nosebleeds or bleeding gums. Signs of anemia such as pallor and shortness of breath. Bruises or pinpoint red spots called petechiae on the skin. Bone or joint pain caused by infiltration of leukemia cells. Unintentional weight loss and loss of appetite. Night sweats and general discomfort. Swollen lymph nodes or enlarged spleen and liver in some cases.

Diagnosis Path: Complete blood count (CBC) to detect abnormalities in blood cells. Peripheral blood smear to examine cell appearance. Bone marrow aspiration and biopsy to identify leukemia cells and genetic mutations. Cytogenetic analysis to detect chromosomal abnormalities, particularly involving 11q23. Molecular testing to identify specific gene mutations in the MLL gene. Additional imaging tests like ultrasound or CT scans may be used to assess organ involvement.

Treatment Protocols: Chemotherapy using drugs that target rapidly dividing cells to induce remission. Targeted therapies designed to interfere with specific genetic abnormalities, such as MLL gene alterations. Stem cell or bone marrow transplants, often considered for suitable candidates after remission. Supportive care including transfusions, antibiotics, and management of side effects. Clinical trials exploring novel therapies for this specific leukemia subtype.